Longeveron Inc. (LGVN) AI Stock Analysis

Longeveron Inc., founded in 2014 and headquartered in Miami, Florida, is a clinical-stage biotechnology firm specializing in cellular therapies for aging-related and life-threatening conditions. Its primary research candidate is LOMECEL-B, an investigational cell-based therapy derived from culture-expanded medicinal signaling cells sourced from the bone marrow of young, healthy adult donors. The company is advancing LOMECEL-B through Phase 1 and 2 clinical trials across multiple indications, including aging frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. As of October 2026, the company operates with 38 employees.

Longeveron has reported volatile top-line results, with a 5-year revenue CAGR of -26.6% from FY2020 to FY2025. Revenue fell 49.9% in FY2025 to $1.2M, following $2.4M in FY2024 and $709,000 in FY2023. Gross margin was 67.0% in FY2025, compared to 78.8% in FY2024 and 31.2% in FY2023. With research and development expenses reaching $12.0M in FY2025, operating margin was -1942.2% and net income was -$22.7M, yielding an EPS of -$3.26. For the trailing twelve months ended June 30, 2026, revenue stood at $1.2M, with quarterly revenue down 9.2% year-over-year and trailing twelve-month EPS at -$9.90.

As of June 30, 2026, Longeveron held $10.1M in cash and short-term investments alongside total debt of $581,000, resulting in net cash of $9.5M. Total assets were $15.5M and shareholders' equity was $10.4M. The company reported a current ratio of 2.63 and a debt-to-equity ratio of 0.06. In FY2025, operating cash flow was -$18.6M and free cash flow was -$18.9M, with capital expenditures of $245,000. To fund operations, the company's share count increased 1467.3% over five years.

With a market capitalization of $4.4M and enterprise value of -$1.2M, Longeveron trades at a price-to-sales ratio of 3.7x and an EV-to-revenue multiple of 9.9x. Its price-to-sales multiple is below the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio stands at 0.8x. On October 16, 2026, the stock closed at $1.39, near its 52-week low of $1.36 and well below its 52-week high of $12.30. Over the past year, shares declined 83.2%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock fell 99.7% while the S&P 500 rose 83.0%.

Analyst coverage consists of 1 Strong Buy, 0 Buys, 1 Hold, 0 Sells, and 0 Strong Sells. The mean price target is $61.25, compared to the last close of $1.39, representing a 4306.5% premium. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$7.63 on revenue of $1.8M. For the following fiscal year, 3 analysts project revenue of $8.7M, reflecting 396.5% growth, and an EPS of -$4.93. Over the last four quarters, the company exceeded EPS estimates 1 time. The next earnings date is November 3, 2026.

This page is an AI-written research summary of Longeveron Inc. (LGVN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LGVN income statement, LGVN balance sheet, LGVN key metrics, LGVN analyst forecast, LGVN chart. See the LGVN stock overview for the latest quote and news.